Downstream processing (DSP) encompasses all operations that occur after the fermentation or cell culture step, transforming crude biological output into a purified product suitable for its intended application. These operations typically include cell harvesting (centrifugation or filtration), cell lysis (if the product is intracellular), clarification, chromatographic purification, concentration, formulation, and sterilization. For biopharmaceuticals, downstream processing can account for 50 to 80 percent of total manufacturing costs, making DSP optimization a critical lever for improving process economics.
The downstream processing requirements vary enormously depending on the product and its application. Pharmaceutical proteins require extensive multi-step purification to achieve high purity and remove host cell proteins, DNA, endotoxins, and process-related impurities. In contrast, industrial enzymes and food-grade proteins may tolerate less stringent purification, enabling simpler and less expensive DSP trains. Companies in the precision fermentation space, such as Perfect Day and New Culture, have invested heavily in developing cost-effective DSP processes that can purify food proteins at commodity-scale economics rather than pharmaceutical-scale costs.
Innovation in downstream processing is critical for the commercial viability of many synthetic biology products. Continuous chromatography, membrane-based separations, and aqueous two-phase extraction are replacing traditional batch purification methods. Companies like Pall (Danaher), Cytiva (formerly GE Healthcare Life Sciences), and Sartorius provide the equipment and consumables that underpin modern DSP operations. The design of production organisms can also significantly impact downstream processing: engineering strains to secrete the target product rather than accumulating it intracellularly can eliminate costly lysis and clarification steps, substantially improving overall process economics.